Key result
Elevated Lp(a) correlates with myocardial fibrosis and scarring in Group II PH secondary to HFpEF.
Why the study?
The role of Lipoprotein(a) [Lp(a)] in myocardial fibrosis within Group II Pulmonary Hypertension secondary to HFpEF remains underexplored.
Is elevated Lp(a) associated with cardiac fibrosis in patients with Group II pulmonary hypertension secondary to HFpEF?
Cohort (n=100)
Is elevated Lp(a) associated with cardiac fibrosis in patients with Group II pulmonary hypertension secondary to HFpEF?
Elevated Lp(a) is associated with myocardial fibrosis and structural remodeling in patients with Group II PH secondary to HFpEF, suggesting its potential utility as a biomarker for risk stratification.
Answers are grounded in this paper and cite their sources.
May support Lp(a) risk stratification in Group II PH-HFpEF; leaves open causal role and need for prospective validation.
BACKGROUND: Group II Pulmonary Hypertension (PH) secondary to Heart Failure with preserved Ejection Fraction (HFpEF) is associated with significant morbidity and mortality. Lipoprotein(a) [Lp(a)] is a novel biomarker implicated in cardiovascular pathology, yet its role in myocardial fibrosis within this population remains underexplored. This study investigates the association between elevated Lp(a) levels and cardiac fibrosis to improve understanding of its prognostic and diagnostic utility. METHODS: This retrospective cohort study included 100 patients with Group II PH secondary to HFpEF. Serum Lp(a) levels were quantified using enzymatic assays, and myocardial fibrosis was assessed using Cardiac Magnetic Resonance Imaging (CMR) techniques, including T1 mapping and late gadolinium enhancement (LGE). Statistical models adjusted for confounding factors. Structural cardiac changes correlated with Lp(a) concentrations. CONCLUSION: Elevated Lp(a) is a key marker of myocardial fibrosis and structural remodeling in Group II PH secondary to HFpEF. Routine Lp(a) measurement may enhance risk stratification and inform therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Albulushi et al. (2025) conducted a cohort in Group II Pulmonary Hypertension secondary to Heart Failure with preserved Ejection Fraction (n=100). Elevated Lipoprotein(a) was evaluated on Myocardial fibrosis assessed using Cardiac Magnetic Resonance Imaging (T1 mapping and late gadolinium enhancement) (p=< 0.01). Elevated Lp(a) was associated with myocardial fibrosis, prolonged native T1 times, and increased odds of myocardial scar formation in Group II PH secondary to HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: